Skip to main content

Table 2 Responsiveness of the GA-VAS at Weeks 1, 2, and 4 (In-clinic Visits)

From: Psychometric evaluation of a visual analog scale for the assessment of anxiety

 

Week 1

Week 2

Week 4

Guyatt's Responsiveness Statistics

   

   Initial responder (n = 121) vs. Non-responder (n = 19)

-1.13

-0.71

-0.79

   Partial responder (n = 90) vs. Non-responder (n = 50)

-0.92

-0.89

-0.86

   Sustained responder (n = 79) vs. Non-responder (n = 32)

-0.91

-0.89

-0.80

Cohen's Effect Size Estimates

   

   Placebo (n = 54) vs. Lorazepam (n = 46)

0.42

0.49

0.29

   Placebo (n = 54) vs. Paroxetine (n = 48)

-0.07

0.59

0.67

  1. Note: Initial responders achieved ≥ 50% reduction in HAM-A scores at Week 1 (regardless of responder status at Weeks 2 and 4); partial responders achieved ≥ 30% reduction in HAM-A scores at Week 1 (regardless of responder status at Weeks 2 and 4); sustained responders achieved ≥ 30% reduction in HAM-A scores at Weeks 1 and 2, and ≥ 50% reduction in HAM-A scores at Week 4. Initial, partial, and sustained responder categories were not mutually exclusive.